United Kingdom: Patent

Artificial intelligence is transforming how pharmaceutical companies identify new therapeutic uses for existing drugs, but this acceleration creates complex intellectual property challenges. As computational methods rapidly generate repurposing candidates, innovators must navigate the tension between filing early to secure priority and waiting for sufficient validation data, while ensuring their second medical use patents provide meaningful commercial protection in an increasingly competitive landscape.

Launching a product while a patent dispute remains unresolved has never been risk‑free, but many companies have taken the view that the commercial upside justified it.

The UK's Intellectual Property Regulation Board has made a crucial determination regarding the equivalence of the new European Qualifying Examination Paper M3 to traditional UK patent examination requirements.